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Abstract Stx1 and Stx2 produced by Shiga toxin-producing
Escherichia coli are cytotoxic due to their N-glycosidase activity
on 28S rRNA. In this study, we have shown that proinflamma-
tory cytokine mRNAs, especially IL-8, were induced by Stx1 and
Stx2 in Caco-2 cells. A non-toxic mutant of Stx1 which lacks
N-glycosidase activity did not induce cytokine mRNAs. IL-8
production at the protein level was enhanced by Stx1 and Stx2,
but not by the mutant Stx1. These results demonstrate that Shiga
toxins induce expression and synthesis of cytokines in Caco-2
cells and their N-glycosidase activity is essential for the
induction.
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1. Introduction
Shiga toxin 1 (Stx1) and Stx2 produced by Shiga toxin-
producing Escherichia coli (STEC) are implicated in bloody
diarrhea, hemorrhagic colitis and hemolytic uremic syndrome
in STEC-infected patients [1]. Shiga toxins share AB5 holo-
toxin molecular structure [2,3] and the holotoxin binds via the
B subunit pentamer to neutral glycolipid globotriaosylcera-
mide (Gb3) on the target cell surface. Shiga toxins are incor-
porated by endocytosis and transported to endoplasmic retic-
ulum by retrograde transport system [4] and the A subunit
hydrolyzes the N-glycoside bond of the adenosine at position
4324 of 28S rRNA [5^7], resulting in inhibition of cellular
protein synthesis and eventual cell death.
Although it is widely accepted that the cytotoxicity of Shiga
toxins is directly responsible for the vascular injury observed
in hemorrhagic colitis and hemolytic uremic syndrome [8], a
possible role of cytokines in the pathogenesis of the disease
has also been suggested [9]. Recently, it was reported that
Stx1 induces cytokine production in monocytes and macro-
phages in culture [9,10]. Stx1 and Stx2 also enhanced inter-
leukin-8 (IL-8) production in T84 cells, a human colon epi-
thelial cell line [11]. However, the involvement of the A
subunit of the toxin in cytokine induction still remains con-
troversial ; the Stx1 B subunit alone has enhanced cytokine
production in T84 cells [11], but not in monocytes and macro-
phages [10]. The importance of the enzymatic activity of the A
subunit of Shiga toxins in the induction of cytokine has not
been assessed.
We have previously reported the development of a non-
toxic mutant of Stx1 in which two amino acids of the A
subunit were replaced, and have shown that the cytotoxicity
of the mutant toxin is 1/300 000 that of the wild-type due to
the lack of N-glycosidase activity [12]. Since the mutant Stx1
di¡ers from wild-type Stx1 only in the potential active site of
N-glycosidase, it is a good tool to assess the importance of the
enzyme activity in cytokine induction by Shiga toxins. In this
report, we examined the e¡ects of the mutant Stx1, in com-
parison with Stx1 and Stx2, on cytokine production and cell
viability of Caco-2 cells, a human colon epithelial cell line.
2. Materials and methods
2.1. Toxins, serum and reagents
Recombinant Stx1, Stx2 and the mutant Stx1 in which glutamic
acid at position 167 and arginine at position 170 of the A subunit
were replaced by glutamine and leucine, respectively (Stx1/E167Q-
R170L), were prepared as described previously [12^14]. The mutant
Stx1 exhibited similar pro¢les of HPLC on a TSK gel G-2000 SW,
polyacrylamide gel disc electrophoresis and SDS-polyacrylamide gel
slab electrophoresis to those exhibited by wild-type Stx1 [14]. Endo-
toxin content of the Shiga toxin preparations was less than 0.016 EU
per mg as determined by the HS Limulus Test (Wako Pure Industries
Ltd., Osaka, Japan). Rabbit anti-Stx1 antiserum was prepared as
described previously [13]. Hybridoma-13C4, which produces a mono-
clonal antibody against B subunit of Stx1, was obtained from the
American Type Culture Collection (Rockville, MD) and its culture
supernatant was used as a source of the monoclonal antibody. Human
recombinant IL-1L was a gift from Dainippon Pharmaceutical Co.
Ltd. (Osaka, Japan). Lipopolysaccharide (LPS) derived from E. coli
O26:B6 was purchased from Sigma Chemical Co. (St. Louis, MO).
2.2. Cell culture
Caco-2 cells were obtained from the American Type Culture Col-
lection and maintained in Dulbecco’s modi¢ed essential medium
(DMEM; Sigma) supplemented with 10% fetal calf serum (Intergen
Inc., Purchase, NY), with 100 U/ml penicillin, 100 Wg/ml streptomycin
and 25 Wg/ml amphotericin B (all from Gibco BRL, Gaithersburg,
MD). Con£uent Caco-2 cells were treated with 2 mM butyric acid
sodium salt (Wako) for 4 days and used for all experiments, since the
treatment of Caco-2 cells had been reported to increase the content of
Gb3, binding of the Stx1 B subunit and sensitivity to Stx1 [15].
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2.3. Detection of cytokine mRNAs by reverse transcription-PCR
(RT-PCR)
Cells were treated for 6 h with 1, 10 or 100 ng/ml of the di¡erent
Shiga toxin preparations, 10 ng/ml of IL-1L or 1 Wg/ml of LPS. In
some experiments, Stx1 was preincubated with rabbit anti-Stx1 serum
(1:500) or normal rabbit serum (1:500) at 37‡C for 2 h prior to the
treatment. Total RNA fraction of the cells was prepared by the
AGPC method [16] and RT-PCR was performed as described previ-
ously [17]. Primers, protocols and the size of products for PCR are
listed in Table 1. The aliquots of PCR products were separated by
electrophoresis in a 2% agarose gel and stained with ethidium bro-
mide.
2.4. Detection of cytokine proteins by ELISA
Cells were treated for 48 h with various concentrations of the di¡er-
ent Shiga toxin preparations, 10 ng/ml of IL-1L or 1 Wg/ml of LPS.
The culture supernatants were collected by centrifugation and ana-
lyzed immediately or stored at 340‡C until use.
ELISA for IL-8 was performed as described previously [18], using
monoclonal mouse anti-human IL-8 antibody (PetroTech EC Ltd.,
London, UK), polyclonal rabbit anti-human IL-8 antibody (Gen-
zyme, Cambridge, MA) and horseradish peroxidase-labeled goat
anti-rabbit IgG (Southern Biotechnology Associates Inc., Birming-
ham, AL). The minimum detection level by this method was 39.4
pg/ml. ELISA for TNF-K, MCP-1 or MIP-1K was also performed
using commercial ELISA kits (RpD Systems, Minneapolis, MN) ac-
cording to the manufacturer’s instructions.
2.5. Assay for cytotoxicity
Cells were treated with various concentrations of the di¡erent Shiga
toxin preparations, 10 ng/ml of IL-1L or 1 Wg/ml of LPS for 72 h.
Relative number of cells was determined using the WST-1 Cell Count-
ing Kit (Wako).
2.6. Inhibition of protein synthesis
Cells cultured in 96-well plates of the multiScreen Assay system
(Millipore, Bedford, MA) were treated for 2 h with various concen-
trations of Shiga toxins. After removal of the toxin-containing me-
dium, cells were incubated with 2 WCi/well of [3H]leucine (DuPont
New England Nuclear, Boston, MA) in leucine-free DMEM at
37‡C for 90 min, washed and treated with 10% TCA solution at
4‡C for 15 min. The wells were washed with 5% TCA solution three
times, dried completely, and radioactivity of the remaining [3H]leucine
in each well was counted by Top Count Microplate Scintillation
Counter (Packard, Meriden, CT) in Microscint 20 Scintillation Cock-
tail (Packard).
2.7. Assay for bindings of the toxins to Gb3
Indicated amounts of Gb3 isolated from porcine erythrocytes
(Wako) were applied to HPTLC plates (Whatman, Clifton, NJ) and
developed in chloroform/methanol/water, 60:35:8 (v/v). After block-
ing with blocking bu¡er (1% bovine serum albumin, 0.15 M Tris-HCl,
pH 7.6), plates were incubated with wild-type or mutant Stx1 in
blocking bu¡er. Bound toxins were detected by hybridoma-13C4 cul-
ture supernatant, biotinylated horse anti-mouse IgG (Vector Labora-
tories Inc., Burlingame, CA) and streptavidin peroxidase (Sigma), and
visualized with peroxidase substrate, 3,3P-diaminobenzidine tetrahy-
drochlorine (Wako). Gb4 isolated from human erythrocytes (Sigma)
was used as a control to con¢rm the speci¢city of the binding. Mono-
clonal antibody against Gb3 (anti-CD77 clone 38-13; Cosmo Bio Co.
Ltd., Tokyo, Japan) and biotinylated rabbit anti-rat IgM antibody
(Zymed Laboratories, San Francisco, CA) were used to detect Gb3
on HPTLC plates.
3. Results
3.1. Induction of cytokine mRNAs in Caco-2 cells by Shiga
toxins
The expression of cytokine mRNAs in Caco-2 cells was
analyzed by RT-PCR. The expression of mRNAs of IL-8,
TNF-K and MCP-1 was induced by 1^100 ng/ml of Stx1
and Stx2 (Fig. 1A). The induction was completely inhibited
by preincubation of Stx1 with anti-Stx1 antiserum but not
with normal serum (Fig. 1B). No induction of cytokine
mRNA was observed by 1 Wg/ml of LPS of E. coli O26:B6
(Fig. 1A). These results indicate that the induction of cytokine
mRNAs could be solely attributed to Stx1 but not to LPS or
to any other bacterial components. Stx1 and Stx2 also in-
duced mRNA expression of MIP-1K and MIP-1L, but not
IL-1L, an inducer of IL-8 in Caco-2 cells [19] (data not
shown).
No induction of cytokine mRNAs of IL-8, TNF-K and
MCP-1 (Fig. 1A) and MIP-1K, MIP-1L and IL-1L (data not
shown) was observed by the mutant Stx1, except for a slight
induction of IL-8 mRNA when treated with 100 ng/ml, as
discussed below.
3.2. Enhancement of IL-8 production by Shiga toxin
The production of the cytokine protein was determined by
ELISA. As shown in Fig. 2, enhancement of IL-8 production
by Stx1 and Stx2 was also observed at the protein level. Treat-
ment with 10 pg/ml of Stx1 and Stx2 enhanced IL-8 produc-
tion, and the enhancement reached its peak at 100 pg/ml of
the toxins. The enhancement decreased at higher doses of the
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Table 1
Primers and conditions for RT-PCR
5P primers (5P-3P) 3P primers (5P-3P) PCR cycles Size of PCR product (bp)
IL-8 ATGACTTCCAAGCTGGCCGTGGCT TCTCAGCCCTCTTCAAAAACTTCTC 27^35a 292
TNF-K GGACGTGGAGCTGGCCGAGGAG CACCAGCTGGTTATCTCTCAGCTC 48^54b 352
MCP-1 ACTGAAACTCGCACTCTCGCCTC TGTCTGGGGAAAGCTAGGGGAAAAT 29^35a 389
MIP-1K TCCTTTCTTGGCTCTGCTGACACTC CTCAGGCACTCAGCTCTAGGTCG 39^45b 335
MIP-1L TGTCCTGTCTCTCCTCATGCTAGTA GCTCAGTTCAGTTCCAGGTCATACA 39^45b 264
IL-1L AAACAGATGAAGTGCTCCTTCCAGG TGGAGAACACCACTTGTTGCTCCA 27^35a 391
GAPDH GGGAGCCAAAAGGGTCATCATCTC CCATGCCAGTGAGCTTCCCGTTC 11^17a 353
aCycles of 94‡C for 1 min, 62‡C for 2 min, and 72‡C for 2 min.
bCycles of 94‡C for 40 s, 62‡C for 1 min, and 72‡C for 90 s.
Fig. 1. Induction of cytokine mRNAs by Shiga toxins in colon epi-
thelial cell line. A: Expression of cytokine mRNAs detected by RT-
PCR, using total RNA extracted from Caco-2 cells treated with Shi-
ga toxins for 6 h. B: Speci¢c inhibition of Stx1-induced cytokine
mRNAs by anti-Stx1 serum. Cytokine mRNA expression detected
by RT-PCR, using total RNA extracted from Caco-2 cells treated
for 6 h after preincubation with serum for 2 h.
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toxins, but was still observed by treatment with up to 100 ng/
ml of both toxins.
IL-8 production was not enhanced by the mutant Stx1 at
concentrations up to 10 ng/ml, and detectable enhancement
was observed at 100 ng/ml. There was no di¡erence in IL-8
production when treated with 1 Wg/ml LPS of E. coli O26:B6
compared to control (LPS-treated, 43.7 þ 8.4 pg/ml vs. con-
trol, 42.7 þ 3.2 pg/ml; Ps 0.1). Treatment with 10 ng/ml of
IL-1L, a positive control, enhanced IL-8 production to
2019.5 þ 96.2 pg/ml.
Determinations of protein levels of TNF-K, MCP-1 and
MIP-1K by ELISA were also performed, but the levels of
these cytokines in culture medium of Caco-2 cells were less
than the corresponding minimal detection levels, even after
the treatment with various concentrations of Shiga toxins or
LPS (data not shown).
3.3. Cytotoxicity of Shiga toxins
Comparable cytotoxicity was observed by Stx1 and Stx2 to
Caco-2 cells (Fig. 3). At 10 pg/ml, neither Stx1 nor Stx2 re-
duced the cell number, but at 100 pg/ml or higher concentra-
tions, both toxins showed cytotoxicity. Cytotoxicity of Shiga
toxins for Caco-2 cells was much lower than for Vero cells,
currently known to be one of the most sensitive cells to Shiga
toxins [20]. The mutant Stx1 (Fig. 3), 10 ng/ml of IL-1L or
1 Wg/ml of LPS of E. coli O26:B6 (data not shown) did not
show any cytotoxicity to Caco-2 cells.
3.4. E¡ect of Shiga toxins on cellular protein synthesis
Comparable inhibition on cellular protein synthesis was
observed by Stx1 and Stx2 in Caco-2 cells (Fig. 3B). The
mutant Stx1 (Fig. 3B), 10 ng/ml of IL-1L or 1 Wg/ml of LPS
of E. coli O26:B6 (data not shown) did not cause any e¡ect
on cellular protein synthesis in Caco-2 cells.
3.5. Binding of the mutant toxin on Shiga toxin receptor, Gb3
To exclude the possibility that the replacement of amino
acids of A subunit of Stx1 causes any change in binding prop-
erty of the toxin to its receptor, the binding of the mutant
Stx1 to Gb3 was assessed on HPTLC. As shown in Fig. 4,
both wild-type and the mutant Stx1 showed similar binding
pattern to puri¢ed Gb3. Double bonds detected on HPTLC
were con¢rmed to be Gb3 by anti-Gb3 staining (data not
shown). No binding of Stx1 to Gb4 was detected (data not
shown). These results indicated that the B subunit of the mu-
tant Stx1 retains the similar binding ability to the receptor.
4. Discussion
This study demonstrated that the N-glycosidase activity of
the A subunit of Shiga toxins is essential to induce cytokines
in a human colon epithelial cell line. Expression of mRNAs of
IL-8, TNF-K, MCP-1, MIP-1K and MIP-1L was induced by
Stx1 and Stx2, but not by the mutant Stx1 which lacked N-
glycosidase activity. IL-8 production was enhanced by Stx1
and Stx2, and the involvement of N-glycosidase activity was
con¢rmed also at the protein level. The reduced level of IL-8
induction at both mRNA and protein levels by the highest
concentration of the mutant Stx1 seems to be comparable to
its reduced activity (1/300 000) [12] as compared with wild-
type Stx1, suggesting that the cytokine-inducing activity is
directly correlated with the enzyme activity. It is interesting
to note that the enzymatic activity is implicated in apparently
opposite activities: inhibition of cellular protein synthesis and
enhancement of the certain cytokine production.
In our preliminary investigations, the increase of IL-8
mRNA by Shiga toxins was more than 100-fold when meas-
ured by competitive RT-PCR, which was comparable to that
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Fig. 3. Cytotoxicity and inhibitory e¡ect in cellular protein synthesis
of Shiga toxins in human colon epithelial cell line. Relative cell
number (A) and relative incorporation of [3H]leucine (B) of Caco-2
cells treated for 72 h and 2 h, respectively, with Stx1 (b), the mu-
tant Stx1 (a) or Stx2 (v) are shown. Means þ S.D. (n = 4) are
shown.
Fig. 4. Binding activity of wild-type and mutant Stx1 to the recep-
tor Gb3. Binding of wild-type or the mutant Stx1 with the indicated
amount of puri¢ed Gb3 on HPTLC are visualized.
Fig. 2. Enhancement of IL-8 protein by Shiga toxins in human co-
lon epithelial cell line. IL-8 concentration measured by ELISA in
culture supernatant of Caco-2 cells treated for 48 h by Stx1 (b), the
mutant Stx1 (a) or Stx2 (v). Means þ S.D. (n = 3) are shown.
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by IL-1L. Compared with the 6^8-fold enhancement of IL-8
production by Shiga toxins at the protein level shown in this
study, the increase of IL-8 mRNA by Shiga toxins was much
greater. This can be partly explained by their inhibitory e¡ect
on cellular protein synthesis and resulting cytotoxicity to
Caco-2 cells. The highest dose of Stx1 caused persistent inhibi-
tion of protein synthesis in Caco-2 cells, but IL-8 production
was still much more abundant than in control; i.e. the en-
hancement of IL-8 synthesis occurs under the condition in
which synthesis of most proteins is inhibited. Under this con-
dition, the induction of IL-8 mRNA may overcome the inhibi-
tion of protein synthesis. The overall e¡ect of the toxins on
protein synthesis may cause the characteristic pattern of dose
dependence of their cytokine-inducing activity.
Recently, many reports have shown that bacterial cytotox-
ins have activities that modify cellular signaling events. For
example, some bacterial cytotoxins have speci¢c activity on
the cellular signaling molecule, Rho: ADP-ribosylation by
Clostridium botulinum toxin C1, C3 and D [21^23] and O-
glucosylation by Clostridium di⁄cile toxin A and B [24,25].
Some other bacterial cytotoxins also have enzymatic activities
in di¡erent events: ADP-ribosyltransferase activity of cholera
toxin produced by Vibrio cholerae activate Gs constitutively,
eventually increasing the cAMP level [26] ; phospholipase C
activity of K toxins of Clostridium perfringens induces expres-
sion and synthesis of intracellular leukocyte adherence mole-
cule-1 and IL-8 [27]. We propose that Shiga toxins have an
activity other than inhibition of cellular protein synthesis, and
this study suggests that RNA N-glycosidase activity of Shiga
toxins stimulates the cellular signaling pathway to induce cy-
tokines.
This study has also demonstrated that 10 pg/ml of Stx1 or
Stx2 is su⁄cient to induce cytokine production in a human
colon epithelial cell line. It has been reported that the mini-
mum e¡ective dose of Stx1 or Stx2 required for cytokine in-
duction was 1 Wg/ml of Stx1 in monocytes or macrophages
[9,10] and 10 ng/ml of Stx1 and Stx2 in T84 cells [11], which is
106- and 104-fold of the CD50 of Shiga toxins to Vero cells,
respectively. The observation that the minimal dose of Shiga
toxins for IL-8 induction is comparable to their cytotoxic dose
to highly sensitive cells such as Vero cells [12] suggests that
similar levels of Shiga toxins could exist in the circulation or
in some regions of STEC-infected patients and show the ac-
tivities of cytotoxicity and cytokine induction.
IL-8 is known to be a chemokine which mainly activates
and chemoattracts neutrophils [28,29]. It has been reported
that neutrophil migration to the intestinal epithelium is ob-
served in STEC infection [30]. Elevated levels of IL-8 in plas-
ma and polymorphoneutrophil activation have been reported
in HUS patients in childhood relative to that of patients only
with diarrhea [31,32]. Activated neutrophil-dependent injury
of the vascular endothelial cells in HUS patients has also been
reported [33]. The human colon epithelial cells are supposed
to be the ¢rst target cells of Shiga toxin, when STEC colonizes
and produces Shiga toxins in the human colon. The cytokine-
inducing activity of Shiga toxins might be relevant to the
pathological and clinical observations in these patients.
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